Brian T. Hill - Concepedia

Author

Brian T. Hill

Cleveland Clinic ORCID

Also Known As

Alex Herrera, B T Hill, B. Hill, B. T Hill, B. T. Hill, B.T. Hill, BRIAN HILL, Brian Hill, Brian T Hill, Brian T. Hill

785

Publications

19.5K

Citations

H-Index

108

Concepts

All Affiliations

Cleveland Clinic The University of Texas MD Anderson Cancer Center Moffitt Cancer Center Washington University in St. Louis The Ohio State University

About

Brian T. Hill is an author at Cleveland Clinic specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	57	4.9K
2	Health Sciences	13	18	534
3	Public Health	6	6	165
4	Education	1	1	21
5	African American Studies	1	1	21

Brian T. Hill

163

Publications

17.8K

Citations

H-Index

Page 1

	Year	Citations
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, New England Journal of Medicine	2017	5.7K
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaAxicabtagene CiloleucelMedicineImmunology	2018	2.2K
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma Michael Wang, Javier Muñoz, André Goy, New England Journal of Medicine	2020	1.7K
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium Loretta J. Nastoupil, Michael D. Jain, Lei Feng, Journal of Clinical Oncology	2020	752
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis Anthony R. Mato, Chadhi Nabhan, Meghan C. Thompson, Haematologica	2018	439
MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies Gaurav S. Choudhary, Sayer Al-harbi, Suparna Mazumder, Cell Death and Disease ImmunologyMtor PathwaysImmunotherapyBcl-2 Inhibitor Abt-199Tumor Biology	2015	356
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo, The Lancet Haematology Hematological MalignancyLymphoid NeoplasiaMedicineHematologyPathology	2020	324
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study Michael Wang, Javier Muñoz, André Goy, Journal of Clinical Oncology	2022	283
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients Anthony R. Mato, Brian T. Hill, Nicole Lamanna, Annals of Oncology Hematological MalignancyLymphoid NeoplasiaOptimal SequencingChronic Lymphocytic LeukemiaMedicine	2017	219
5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1) Sattva S. Neelapu, Caron A. Jacobson, Armin Ghobadi, Blood	2023	215

Page 1